Studies with anthracyclines in pediatric acute nonlymphocytic leukemia.
The anthracyclines, daunomycin and Adriamycin, have become two of the most important chemotherapeutic agents in the treatment of pediatric acute nonlymphocytic leukemia. Data are presented on 306 children treated after initial diagnosis with an anthracycline or one of the chemotherapeutic agents. The remission rate was 65%. When not used during maintenance therapy, the anthracyclines have been shown to be effective in inducing a second remission even though the drug was used during initial therapy. An ongoing randomized study utilizing Adriamycin in induction of remission and during maintenance therapy is also discussed.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D001374:Azacitidine / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000008:administration & dosage / Q000009:adverse effects; D011897:Random Allocation; D012737:Sex Factors
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D004317:Doxorubicin; D001374:Azacitidine; D003630:Daunorubicin